These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35383492)

  • 1. The Twilight Zone: Oxybutynin Overuse Exacerbating Delirium.
    Marthi S; Pomerantz MA; Mernan AJ; Berlow YA
    J Geriatr Psychiatry Neurol; 2022 Nov; 35(6):840-845. PubMed ID: 35383492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists.
    Welk B
    Eur Urol Focus; 2023 Jan; 9(1):168-171. PubMed ID: 35987891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of delirium associated with antimuscarinics in older adults: A case-time-control study.
    Nishtala PS; Chyou TY
    Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):883-891. PubMed ID: 35587029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications.
    Welk B; Etaby K; McArthur E; Chou Q
    Neurourol Urodyn; 2022 Jan; 41(1):348-356. PubMed ID: 34719044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
    Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):69-71. PubMed ID: 33497068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
    Aaron LE; Morris TJ; Jahshan P; Reiz JL
    Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe anticholinergic drug-induced delirium in a young adult after renal transplantation.
    Götz AK; Reinhold SW; Szecsey A; Banas B; Krämer BK
    Transpl Int; 2009 Feb; 22(2):249-50. PubMed ID: 18786150
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
    This document was developed by the American Urogynecologic Society (AUGS) Guidelines Committee with the assistance of Tonya N. Thomas, MD, and Mark D. Walters, MD. This document reflects clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Its content is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient.
    Female Pelvic Med Reconstr Surg; 2017; 23(3):177-178. PubMed ID: 28441276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
    Araklitis G; Robinson D; Cardozo L
    Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.